Highlights and Quick Summary
- Non-operating Interest Expenses for the quarter ending June 29, 2021 was $406 Thousand (a 74.25% increase compared to previous quarter)
- Year-over-year quarterly Non-operating Interest Expenses increased by 70.59%
- Annual Non-operating Interest Expenses for 2020 was $1.06 Million (a 25.86% increase from previous year)
- Annual Non-operating Interest Expenses for 2019 was $843 Thousand (a -73.19% decrease from previous year)
- Annual Non-operating Interest Expenses for 2018 was $3.14 Million (a 0.87% increase from previous year)
- Twelve month Non-operating Interest Expenses ending June 29, 2021 was $1.03 Million (a 7.15% increase compared to previous quarter)
- Twelve month trailing Non-operating Interest Expenses decreased by -10.32% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
| 29 Jun '21 | 30 Mar '21 | 30 Dec '20 | 29 Sep '20 |
|---|---|---|---|
| $1.03 Million | $965 Thousand | $1.06 Million | $1.15 Million |
Visit stockrow.com/ORGS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Non-operating Interest Expenses of Orgenesis Inc.
Most recent Non-operating Interest Expensesof ORGS including historical data for past 10 years.Interactive Chart of Non-operating Interest Expenses of Orgenesis Inc.
Orgenesis Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $0.41 | $0.23 | – | – | – |
| 2020 | $0.16 | $0.24 | $0.34 | $0.33 | $1.06 |
| 2019 | $0.25 | $0.45 | $0.05 | $0.1 | $0.84 |
| 2018 | – | $-0.61 | $1.07 | $2.68 | $3.14 |
| 2017 | – | – | $-0.05 | $2.08 | $2.45 |
| 2016 | – | $2.08 | $0.0 | $0.0 | – |
| 2012 | – | – | – | – | $0.0 |
Business Profile of Orgenesis Inc.
Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.